Legal & General Group Plc grew its stake in Editas Medicine Inc (NASDAQ:EDIT) by 3.1% during the first quarter, HoldingsChannel.com reports. The firm owned 35,773 shares of the company’s stock after buying an additional 1,091 shares during the period. Legal & General Group Plc’s holdings in Editas Medicine were worth $746,000 at the end of the most recent quarter.
Several other hedge funds also recently bought and sold shares of the company. Principal Financial Group Inc. acquired a new stake in shares of Editas Medicine in the 4th quarter valued at about $214,000. Rhumbline Advisers raised its stake in shares of Editas Medicine by 9.3% in the 4th quarter. Rhumbline Advisers now owns 71,873 shares of the company’s stock valued at $2,128,000 after purchasing an additional 6,114 shares during the period. Swiss National Bank raised its stake in shares of Editas Medicine by 2.6% in the 4th quarter. Swiss National Bank now owns 85,300 shares of the company’s stock valued at $2,526,000 after purchasing an additional 2,200 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Editas Medicine by 5.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 316,001 shares of the company’s stock valued at $9,357,000 after purchasing an additional 16,818 shares during the period. Finally, FMR LLC raised its stake in shares of Editas Medicine by 75.2% in the 4th quarter. FMR LLC now owns 160,794 shares of the company’s stock valued at $4,761,000 after purchasing an additional 68,997 shares during the period. 81.99% of the stock is currently owned by institutional investors.
Several equities analysts have recently weighed in on EDIT shares. Morgan Stanley decreased their price objective on Editas Medicine from $30.00 to $27.00 and set an “equal weight” rating for the company in a report on Monday, May 11th. Zacks Investment Research cut Editas Medicine from a “buy” rating to a “hold” rating and set a $29.00 price objective for the company. in a report on Monday, June 1st. ValuEngine upgraded Editas Medicine from a “hold” rating to a “buy” rating in a report on Friday, March 13th. SunTrust Banks started coverage on Editas Medicine in a report on Thursday, June 18th. They issued a “buy” rating and a $45.00 price objective for the company. Finally, Chardan Capital restated a “buy” rating and issued a $55.00 price objective on shares of Editas Medicine in a report on Friday, June 12th. Six research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $37.50.
Editas Medicine (NASDAQ:EDIT) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.69) EPS for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.10. Editas Medicine had a negative return on equity of 63.21% and a negative net margin of 588.05%. The business had revenue of $5.70 million during the quarter, compared to analysts’ expectations of $6.73 million. During the same quarter last year, the company posted ($0.60) earnings per share. Editas Medicine’s quarterly revenue was up 171.4% on a year-over-year basis. Research analysts forecast that Editas Medicine Inc will post -3.02 earnings per share for the current year.
About Editas Medicine
Editas Medicine, Inc operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas.
Further Reading: Why are analyst ratings important in trading stocks?
Want to see what other hedge funds are holding EDIT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Editas Medicine Inc (NASDAQ:EDIT).
Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.